Metastatic Breast Cancer – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Breast Cancer (HR+VE/ HER2 -VE) is the most common malignancy in young women worldwide, accounting for an estimated 30% of new cancer diagnoses and 25% of cancer deaths. Patients with metastatic breast cancer are heterogeneous patients whose prognoses and clinical courses can vary depending on host factors, such as comorbidity and age, and on tumor factors, such as hormone-receptor status, grade, and anatomical site of disease. Although the median survival time for patients with metastatic breast cancer is 2-4 years, subsets of patients with either indolent or limited metastatic disease may have prolonged survival times. Approximately 6%-10% of patients will present with metastatic disease at diagnosis. Despite our newer strategies and treatments for MBC, their impact on survival is small. Currently, MBC is largely considered incurable, and the treatment goals are generally palliative. Nevertheless, with the development of newer agents, prolongation of survival has become a goal in the metastatic setting.

 

HER2+ patients in the first line receive trastuzumab plus pertuzumab + taxane, and the second-line receive trastuzumab emtansine preferentially.

HR+/HER2(-) patients in the first line receive a hormone agent with or without a CDK inhibitor, preferentially palbociclib, and in the second-line receive hormone therapy with or without a CDK4/6 inhibitor regardless of BRCA status.

For PD-L 1(+) triple-negative breast cancer (TNBC) patients, atezolizumab plus nab-paclitaxel has seen rapid uptake since its approval in August 2019 and has become the standard of care in the first-line setting. Taxane-based regimens are most often utilized for PD-L 1(-) triple-negative breast cancer (TNBC) patients.

 

The competitive landscape of Metastatic Breast Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Metastatic Breast Cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Metastatic Breast Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Metastatic Breast Cancer– Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Tenalisib (RP6530)        Rhizen Pharmaceuticals AG      Phase 2

2          Abemaciclib      Eli Lilly and Company    Phase 2

3          Pertuzumab and Trastuzumab   Genentech, Inc. Phase 2

4          Ixabepilone Injection      Allarity Therapeutics      Phase 2

5          SYD985            Byondis B.V      Phase 3

6          ARX788            Ambrx, Inc.       Phase 2

7          BP-C1  Meabco A/S      Phase 1

8          MEN1611         Menarini Group Phase 1

9          Abraxane          Orinove, Inc.     Phase 2

10        Enobosarm       Veru Inc.           Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more